Metastatic triple‑negative breast cancer (mTNBC) remains one of the most aggressive and devastating types of breast cancer, and it affects Black women at disproportionate rates. For many years, treatment options in the earliest stages of metastatic care have been limited. Now, the FDA has approved a first-line treatment of Metastatic Triple-Negative Breast Cancer, called Trodelvy. This new treatment can offer renewed hope for women battling mTNBC.
Why This Matters for Black Women
mTNBC strikes earlier and more often in communities of color. As noted, “TNBC disproportionally impacts younger, premenopausal, and Black and Hispanic women.” This means Black women are more likely to face this diagnosis at ages when they are working, parenting, caregiving, and supporting their families. This amplifies the emotional and financial impact on their bodies.
However, the disease also progresses more quickly than other breast cancers. The data shows that “the average time to metastatic recurrence for mTNBC is approximately 2.6 years compared with 5 years for other breast cancers”. Once the disease becomes metastatic, outcomes begin to worsen. It is evident because the five-year survival rate is 12% compared to 28% for those with other types of metastatic Breast Cancer.
These numbers reflect both the biological aggressiveness and systemic barriers many Black women may face. Many Black women experience delays in diagnosis, limited access to biomarker testing, and fewer opportunities to receive specialized cancer care.
A Historic Gap in First‑Line Treatment
But, for over two decades, first‑line treatment options for mTNBC have been extremely limited. It has been shown that over 50% of patients do not receive treatment beyond the first line. This means that the first therapy offered is oftentimes the only chance to slow the disease. Black women are more likely to be diagnosed at advanced stages, which emphasizes this harmful gap.
Chemotherapy has been the backbone of first-line care for a while, even though mTNBC is less responsive to many standard treatments. And families have often had to navigate care plans that offered little hope for slowing the disease early, which is when it matters the most. This lack of options has contributed to the disproportionate survival gap many Black women face.
What the New FDA Approvals Change
Recent FDA approval of a new frontline antibody drug represents meaningful progress in healthcare. This approval introduced Trodelvy as a Trop‑2‑directed antibody‑drug conjugate (ADC). It is now approved for first‑line treatment either alone or in combination with KEYTRUDA or KEYTRUDA QLEX, for tumors expressing PD‑L1. Understanding PD-L1 is essential because it is an adaptive mechanism that helps evade the immune system. This is the first PD‑L1 inhibitor plus Trop‑2‑directed ADC regimen in advanced mTNBC.
In clinical trials, the combination reduced the risk of disease progression or death by 35% compared with KEYTRUDA plus chemotherapy. The new treatment kept the cancer under control for longer periods. With Trodelvy alone, women remained stable for about 12.2 months, compared with about 7.2 months with an older chemotherapy regimen. When Trodelvy was combined with KEYTRUDA, women remained stable for about 16.5 months, compared to about 9.2 months on the previous KEYTRUDA‑plus‑chemotherapy option.
Why This Matters
For Black women, these additional months of stability carry a different weight. And having treatment that holds the cancer back longer can create space to manage life, maintain routines, and prepare for what comes next. This buffer is provided for a disease that rarely gives one. The ability to start with options such as Trodelvy, with or without KEYTRUDA or KEYTRUDA QLEX, is critical. It offers a greater sense of hope and a positive step forward toward more equitable care for the women most affected by mTNBC.
For additional information, including side effects, please visit the Trodelvy and Keytruda websites.
Sources
U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple Negative Breast Cancer
